Compare WST & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WST | AFRM |
|---|---|---|
| Founded | 1923 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.9B | 28.3B |
| IPO Year | 2004 | 2020 |
| Metric | WST | AFRM |
|---|---|---|
| Price | $337.66 | $71.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 25 |
| Target Price | ★ $325.86 | $84.52 |
| AVG Volume (30 Days) | 313.4K | ★ 4.7M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | 1.49 | ★ 3586.67 |
| EPS | 4.07 | ★ 5.53 |
| Revenue | $2,886,900,000.00 | ★ $4,261,082,000.00 |
| Revenue This Year | $6.76 | $30.78 |
| Revenue Next Year | $6.22 | $23.95 |
| P/E Ratio | $83.53 | ★ $13.08 |
| Revenue Growth | 1.95 | ★ 32.15 |
| 52 Week Low | $223.83 | $42.10 |
| 52 Week High | $386.00 | $92.56 |
| Indicator | WST | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 43.43 |
| Support Level | $323.60 | $71.33 |
| Resistance Level | $359.48 | $78.97 |
| Average True Range (ATR) | 7.28 | 3.89 |
| MACD | -1.13 | -0.52 |
| Stochastic Oscillator | 18.37 | 10.97 |
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.